$TLSA

Tiziana Life Sciences (TLSA) completed dosing in its Phase 2 trial of intranasal foralumab for early or mild Alzheimer's, with topline data expected in Q1 2027. The trial, assessing safety, tolerability, and efficacy, includes foralumab alone and in combination with lecanemab or donanemab. Key endpoints include changes in neuroinflammation, cognitive function, and fluid biomarkers.

MongoDB (MDB) raised long-term growth targets, with Bank of America maintaining a Buy rating. Tiziana Life Sciences (TLSA) seeks FDA orphan drug designation for foralumab. Apple (AAPL) plans a Siri-powered smart-home hub. Salesforce (CRM) acquired Listen Labs, shares up 3.2%. Boeing (BA) won a multi-billion-dollar Navy contract. Conagra (CAG) shares fell 4.6% after Q1 revenue decline. HPE (HPE) shares rose 5% after a $1.2B order from Vultr.

Tiziana Life Sciences (TLSA) filed for FDA Orphan Drug Designation for intranasal foralumab to treat Multiple System Atrophy (MSA), a rare neurodegenerative disease. The company is conducting a Phase 2a trial. If granted, the designation could provide market exclusivity and other benefits. Foralumab is also being studied for other neuroinflammatory conditions.

Micron (MU) may report Q4 EPS in mid-$30s due to rising DRAM/NAND prices, per Wedbush. MongoDB (MDB) raised revenue growth targets. Apple (AAPL) plans a Siri-powered smart-home hub. Boeing (BA) won a $20B Navy contract. Conagra (CAG) Q1 revenue fell 1.4% to $2.6B. HPE (HPE) secured a $1.2B order. NCLH expects Q3 results to exceed guidance. US GDP revised to 2.2% growth, core PCE inflation eased to 3.0% YoY.

Tiziana Life Sciences (TLSA) has dosed the first three patients in a Phase 2a ALS trial of its nasal antibody foralumab. The Healey ALS MyMatch BANYAN trial, sponsored by Tiziana and co-funded by the ALS Association, will enroll 44 early-stage ALS patients. The trial's primary endpoint is safety and tolerability, with secondary endpoints including immune and biomarker changes. The study is being conducted at multiple U.S. centers and is led by Suma Babu and James Berry.

US stocks closed lower as Treasury yields rose and Iran-US talks stalled, raising oil prices and inflation concerns. The Dow, S&P 500, and Nasdaq fell 0.7%, 0.8%, and 0.9% respectively. Nvidia authorized a $150B share buyback, and Meta launched an AI platform. Investors await economic data, including jobs and PCE inflation reports.

Tiziana Life Sciences (TLSA) completed patient visits in its Phase 2a trial for intranasal foralumab in non-active secondary progressive multiple sclerosis. The trial enrolled 48 patients and aims to evaluate safety, tolerability, and efficacy. The company expects to announce topline data in October. Foralumab is Tiziana's lead development candidate.

Aethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.

Tiziana Life Sciences (TLSA) announced a clinical trial collaboration to test intranasal foralumab with anti-CD20 therapy for RRMS patients. The company has no revenue, a GF Score of 23/100, and $1.0M in insider purchases over 12 months. TLSA's market cap is approximately $103M.

Tiziana Life Sciences (TLSA) signed an MOU with King Abdullah International Medical Research Center to collaborate on a clinical trial for relapsing-remitting multiple sclerosis using intranasal foralumab. The trial will combine foralumab with existing anti-CD20 therapy. Tiziana's CEO, Ivor Elrifi, noted this does not change their ongoing Phase 2 trial for non-active secondary progressive multiple sclerosis, with results expected in October 2026.